NCT02293317View on ClinicalTrials.gov

Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

June 30, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

M-001

A recombinant epitope based universal vaccine against seasonal and pandemic influenza

DRUG

TIV

HA based seasonal influenza vaccine, for 2014/15 seson

OTHER

Saline

Placebo

Trial Locations (1)

Unknown

Clinical Research Center, Tel-Aviv Sourasky Medical Center, Tel Aviv

Sponsors
All Listed Sponsors
lead

BiondVax Pharmaceuticals ltd.

INDUSTRY